Background-Liquid diets given enterally combined with 'bowel rest' are efficacious in the treatment ofactive Crohn's disease, but rapid recrudescence of gastrointestinal symptoms after resumption of a normal diet is common.
Therefore, alternative treatments have been sought. Exclusive enteral nutrition using formulated food has been increasingly used as primary treatment of active Crohn's disease. 3 4 Efficacy has been shown in controlled clinical trials, but symptoms recur in a high percentage of patients within several months of stopping the diet treatment.5 Longterm exclusive enteral nutrition and avoidance of a normal diet is an unreasonable therapeutic option. Compliance is much better, however, when normal food is permitted during the day. Such supplementary nocturnal nasogastric tube feeding is often used in children as a means of improving growth. 6 We have found that patients using such supplementary feeding regimens also experience fewer relapses of gastrointestinal symptoms. To examine this question formally, we reviewed our experience with enteral nutrition as primary treatment of active Crohn's disease in children and adolescents. We designed a historical cohort study to discover if continued supplementary enteral nutrition without other dietary restrictions is associated with prolongation of remission.
Methods

Patients
The medical records of all patients with active Crohn's disease treated by exclusive nasogastric tube feeding of an elemental or semielemental liquid diet at the Hospital for Sick Children, Toronto, between January 1986 and December 1992 were reviewed. The formula used varied according to the time period, but otherwise all patients were treated with an identical protocol as outlined below.
Patients were admitted to hospital to learn the techniques of nasogastric tube insertion and formula infusion. Infusion rates of formulated food were increased in a stepwise fashion to provide the recommended dietary allowance (RDA)7 of total energy and protein during a 10 to 14 hours overnight infusion. Only clear fluids were permitted by mouth during the day. Patients were discharged from hospital when comfortable with the regimen, usually after five to seven days. Exclusive enteral nutrition was then continued at home. The child removed Success of exclusive enteral nutrition was defined as a decline in PCDAI to ss<20 at first follow up. Treatment failure was defined as the PCDAI remaining >20 or the patient being unable to tolerate the feeding regimen. Among responders relapse was defined by return of clinical symptoms necessitating additional treatment and associated rise in PCDAI to >20.
Assessment ofpatient acceptance A questionnaire was given to all children who had received exclusive enteral nutrition as primary treatment. Patients were asked to report adverse effects of nasogastric tube feeding and were questioned specifically about night-time wakening, nausea, vomiting, abdominal cramping, and loose stools. Patients who had previously been treated with oral corticosteroids were asked to state which, if either, of the two treatments they preferred. The questionnaire received the prior approval of The Human Subjects Review Committee at the Hospital for Sick Children, Toronto.
Statistical analysis
All data are expressed as mean (SD). Baseline values for PCDAI, age, and disease duration in the two cohorts were compared using the Student's t test. PCDAI and laboratory parameters at baseline and at first follow up visit and linear growth during the years before and after exclusive enteral nutrition were compared by the paired Student's t test. Comparisons of different anatomical locations were performed using two tailed Fisher's exact test. Rates of clinical relapse were compared using the log rank procedure. Changes in height velocity in the two groups were compared using the Student's t test.
Results
Between January 1986 and December 1992, 65 children and adolescents received exclusive elemental or semi-elemental liquid diets by nocturnal nasogastric infusion to treat active Crohn's disease. The formulated food used was either Vital HN (Abbott Laboratories, n= 51), Vivonex (Sandoz Nutrition, n= 8), or Peptamen (Clintec Nutrition, n=6). Table I summarises the characteristics at baseline. The study excluded an additional seven growth impaired patients without overt symptoms of intestinal inflammation, who were treated with enteral nutrition as a supplement to a normal diet but without an initial period of bowel rest. Another two patients with active Crohn's disease given with liquid diet treatment combined with bowel rest were excluded because immunosuppressive drugs were started simultaneously and may have contributed to disease control.
The PCDAI had fallen to <20 in 47 attributable to intolerance to or non-compliance with the nasogastric tube feeding. 
The mean height velocity of the remaining 24 patients receiving supplementation with complete before and after treatment data was greater during the treatment year (6-1 (4.2 cm)) than during the previous year (3.2 (1.6 cm)) (p<0.001). For the seven non-supplemented patients with complete before and after treatment measurements, the mean height velocity during the second year (4.2 (4.5 cm)) did not differ significantly from that recorded during the previous year (3-8 (1.2 cm)). Comparing paired data between the two cohorts, the mean change in height velocity was 2.87 cm/year among those continuing supplements versus 0.4 cm/year among those who did not (p=0 057).
Results ofquestionnaire Questionnaires concerning acceptance of enteral nutrition were returned by 52 of 65 patients (80%). As Table III 18 (35) considerable. 18 (35) Growth impairment is a common complica-2 (4) tion of childhood Crohn's disease. In our insti-11 (21) 30 (58) tution height velocity fell below the normal 22 (42) prepubertal rate (-4 cm per year) for at least two individual years and bone age was n=44 accordingly delayed in 50% of a group of 100 20 (45) children who were at Tanner stage 1 or 2 of 12 (27) pubertal development at the time of diagnosis. 19 12 (27) The important mechanism of the observed 27 Over 60% of a group of 30 patients treated in randomised fashion with either an elemental or a polymeric liquid diet had inflammation confined to the colon, but the response rate overall was 70%.5 Hence prospective studies do not support restriction of enteral nutritional treatment to patients with active small intestinal inflammation.
We have been impressed that young patients adapt to nocturnal nasogastric tube feeding better than would originally have been expected. With instruction and encouragement provided by experienced nursing staff, intolerance was infrequent in the acute phase of treatment. Reported intolerance among predominantly adults in clinical trials versus corticosteroids is 21% overall, but is much greater when oral administration of formulated food is initially attempted than when, as in our study, the nasogastric route is used from the outset.31
The results of our questionnaire show that enteral nutrition is accompanied by frequent adverse effects such as night-time wakening, nausea, loose stools, and vomiting. However, the beneficial effects on disease activity, the improved nutritional state, and improved linear growth make enteral nutrition acceptable to young patients despite these inconveniences.
In the long term, allowing normal food at times when family and friends are eating is particularly important in achieving compliance. The findings of this historical cohort study suggest that administration of formulated food is useful in controlling activity of Crohn's disease even when dietary restrictions are not imposed. The 
